188 related articles for article (PubMed ID: 24726915)
1. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells.
Machado-Neto JA; Lazarini M; Favaro P; Franchi GC; Nowill AE; Saad ST; Traina F
Exp Cell Res; 2014 Jun; 324(2):137-45. PubMed ID: 24726915
[TBL] [Abstract][Full Text] [Related]
2. ANKHD1 promotes proliferation and invasion of non‑small‑cell lung cancer cells via regulating YAP oncoprotein expression and inactivating the Hippo pathway.
Liu XF; Han Q; Rong XZ; Yang M; Han YC; Yu JH; Lin XY
Int J Oncol; 2020 May; 56(5):1175-1185. PubMed ID: 32319569
[TBL] [Abstract][Full Text] [Related]
3. ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.
Nguyen LT; Tretiakova MS; Silvis MR; Lucas J; Klezovitch O; Coleman I; Bolouri H; Kutyavin VI; Morrissey C; True LD; Nelson PS; Vasioukhin V
Cancer Cell; 2015 Jun; 27(6):797-808. PubMed ID: 26058078
[TBL] [Abstract][Full Text] [Related]
4. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.
Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J
Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929
[TBL] [Abstract][Full Text] [Related]
5. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
6. ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth.
Dhyani A; Machado-Neto JA; Favaro P; Saad ST
Eur J Cancer; 2015 Jan; 51(2):252-9. PubMed ID: 25483783
[TBL] [Abstract][Full Text] [Related]
7. ANKHD1 silencing suppresses the proliferation, migration and invasion of CRC cells by inhibiting YAP1-induced activation of EMT.
Yao P; Li Y; Shen W; Xu X; Zhu W; Yang X; Cao J; Xing C
Am J Cancer Res; 2018; 8(11):2311-2324. PubMed ID: 30555746
[TBL] [Abstract][Full Text] [Related]
8. The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling.
Yao PA; Wu Y; Zhao K; Li Y; Cao J; Xing C
Cell Death Dis; 2022 Feb; 13(2):103. PubMed ID: 35110552
[TBL] [Abstract][Full Text] [Related]
9. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
[TBL] [Abstract][Full Text] [Related]
11. Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Kim TD; Jin F; Shin S; Oh S; Lightfoot SA; Grande JP; Johnson AJ; van Deursen JM; Wren JD; Janknecht R
J Clin Invest; 2016 Feb; 126(2):706-20. PubMed ID: 26731476
[TBL] [Abstract][Full Text] [Related]
12. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.
Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
Cancer Lett; 2018 Jun; 423():36-46. PubMed ID: 29452146
[TBL] [Abstract][Full Text] [Related]
13. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.
Selth LA; Das R; Townley SL; Coutinho I; Hanson AR; Centenera MM; Stylianou N; Sweeney K; Soekmadji C; Jovanovic L; Nelson CC; Zoubeidi A; Butler LM; Goodall GJ; Hollier BG; Gregory PA; Tilley WD
Oncogene; 2017 Jan; 36(1):24-34. PubMed ID: 27270433
[TBL] [Abstract][Full Text] [Related]
14. Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth.
Maruyama J; Inami K; Michishita F; Jiang X; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Miyamura N; Hirayama J; Nishina H; Nogawa D; Yamamoto K; Hata Y
Mol Cancer Res; 2018 Feb; 16(2):197-211. PubMed ID: 29061667
[TBL] [Abstract][Full Text] [Related]
15. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
[TBL] [Abstract][Full Text] [Related]
16. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma.
Wu DM; Wang S; Wen X; Han XR; Wang YJ; Shen M; Fan SH; Zhang ZF; Shan Q; Li MQ; Hu B; Lu J; Chen GQ; Zheng YL
Cell Death Dis; 2018 Sep; 9(10):947. PubMed ID: 30237435
[TBL] [Abstract][Full Text] [Related]
17. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.
Wang G; Lu X; Dey P; Deng P; Wu CC; Jiang S; Fang Z; Zhao K; Konaparthi R; Hua S; Zhang J; Li-Ning-Tapia EM; Kapoor A; Wu CJ; Patel NB; Guo Z; Ramamoorthy V; Tieu TN; Heffernan T; Zhao D; Shang X; Khadka S; Hou P; Hu B; Jin EJ; Yao W; Pan X; Ding Z; Shi Y; Li L; Chang Q; Troncoso P; Logothetis CJ; McArthur MJ; Chin L; Wang YA; DePinho RA
Cancer Discov; 2016 Jan; 6(1):80-95. PubMed ID: 26701088
[TBL] [Abstract][Full Text] [Related]
18. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
19. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
Ota M; Sasaki H
Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome.
Rybarczyk A; Klacz J; Wronska A; Matuszewski M; Kmiec Z; Wierzbicki PM
Oncol Rep; 2017 Jul; 38(1):427-439. PubMed ID: 28504812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
